Published in Br J Cancer on August 17, 2001
Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia (2008) 1.26
Targeting fibroblast growth factor pathways in prostate cancer. Clin Cancer Res (2013) 0.98
Inducing endoderm differentiation by modulating mechanical properties of soft substrates. J Tissue Eng Regen Med (2012) 0.89
PTRF/Cavin-1 decreases prostate cancer angiogenesis and lymphangiogenesis. Oncotarget (2013) 0.89
Management of low risk prostate cancer-active surveillance and focal therapy. Nat Rev Clin Oncol (2014) 0.88
Active surveillance and focal therapy for low-intermediate risk prostate cancer. Transl Androl Urol (2015) 0.82
Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts. BMC Cancer (2010) 0.80
Prognostic role of vascular endothelial growth factor in prostate cancer: a systematic review and meta-analysis. Int J Clin Exp Med (2015) 0.79
Prostate cancer stroma: an important factor in cancer growth and progression. Bosn J Basic Med Sci (2015) 0.77
Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. World J Urol (2015) 0.77
VEGF is associated with the poor survival of patients with prostate cancer: a meta-analysis. Transl Androl Urol (2013) 0.76
Does true Gleason pattern 3 merit its cancer descriptor? Nat Rev Urol (2016) 0.76
Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. Cancer Causes Control (2016) 0.75
Non-caveolar caveolin-1 expression in prostate cancer cells promotes lymphangiogenesis. Oncoscience (2015) 0.75
The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population. Korean J Urol (2015) 0.75
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (1990) 13.41
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 7.49
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol (1993) 6.55
Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest (1989) 5.71
Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev (1992) 5.50
Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun (1992) 5.31
Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res (1995) 4.84
Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol (1998) 3.12
Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci U S A (1993) 3.01
Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer (1996) 2.96
How tumors become angiogenic. Adv Cancer Res (1996) 2.63
Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun (1992) 2.47
Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst (1995) 2.44
Prostatic carcinoma. N Engl J Med (1979) 2.01
Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol (1997) 1.98
Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells. Proc Natl Acad Sci U S A (1992) 1.76
Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology (1999) 1.71
Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol (1997) 1.68
Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat (1995) 1.67
Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer (1994) 1.65
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res (1997) 1.32
Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res (2000) 1.24
Fgf-8 expression in the post-gastrulation mouse suggests roles in the development of the face, limbs and central nervous system. Mech Dev (1994) 1.22
Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate (2000) 1.21
FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene (1999) 1.21
Topography of neovascularity in human prostate carcinoma. Cancer (1995) 1.18
Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: expression of VEGF in the human endometrium. J Pathol (1998) 1.17
Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab (1996) 1.16
Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate (2000) 1.12
Structure and sequence of human FGF8. Genomics (1996) 1.09
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol (1999) 1.09
Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis. J Pathol (1998) 1.04
Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br J Urol (1996) 0.98
aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. J Pathol (1999) 0.98
Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer (1996) 0.97
Hormonal therapy of prostatic cancer. Cancer (1980) 0.93
Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma. Prostate (2000) 0.87
The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells. Cancer Res (2000) 0.87
Three-dimensional structure of the beta subunit of E. coli DNA polymerase III holoenzyme: a sliding DNA clamp. Cell (1992) 5.77
Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA. Cell (1996) 5.38
UmuD'(2)C is an error-prone DNA polymerase, Escherichia coli pol V. Proc Natl Acad Sci U S A (1999) 4.24
The Zarit Burden Interview: a new short version and screening version. Gerontologist (2001) 3.95
Roles of E. coli DNA polymerases IV and V in lesion-targeted and untargeted SOS mutagenesis. Nature (2000) 3.95
Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? Lancet (1993) 3.54
Mechanism of the sliding beta-clamp of DNA polymerase III holoenzyme. J Biol Chem (1991) 3.37
DNA polymerase III holoenzyme: structure and function of a chromosomal replicating machine. Annu Rev Biochem (1995) 3.27
Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc Natl Acad Sci U S A (1994) 3.03
Speckle tracking methods for ultrasonic elasticity imaging using short-time correlation. IEEE Trans Ultrason Ferroelectr Freq Control (1999) 2.97
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 2.76
A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol (2000) 2.73
Crystal structure of the processivity clamp loader gamma (gamma) complex of E. coli DNA polymerase III. Cell (2001) 2.68
Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci (2001) 2.64
Trading places on DNA--a three-point switch underlies primer handoff from primase to the replicative DNA polymerase. Cell (1999) 2.51
Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med (2000) 2.48
Mechanism of processivity clamp opening by the delta subunit wrench of the clamp loader complex of E. coli DNA polymerase III. Cell (2001) 2.39
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer (2011) 2.28
Screening for prostate cancer in the UK. Seems to be creeping in by the back door. BMJ (2001) 2.22
Biochemical basis of SOS-induced mutagenesis in Escherichia coli: reconstitution of in vitro lesion bypass dependent on the UmuD'2C mutagenic complex and RecA protein. Proc Natl Acad Sci U S A (1998) 2.22
Crystal structure of the delta' subunit of the clamp-loader complex of E. coli DNA polymerase III. Cell (1997) 2.16
Sliding clamps of DNA polymerases. J Mol Biol (1993) 2.11
Clamp loading, unloading and intrinsic stability of the PCNA, beta and gp45 sliding clamps of human, E. coli and T4 replicases. Genes Cells (1996) 2.09
Hospital volume and stroke outcome: does it matter? Neurology (2007) 2.07
Overproduction, purification, and characterization of EBNA1, the origin binding protein of Epstein-Barr virus. J Biol Chem (1991) 2.06
Ambulatory urodynamics. Br J Urol (1996) 2.06
Activity of the purified mutagenesis proteins UmuC, UmuD', and RecA in replicative bypass of an abasic DNA lesion by DNA polymerase III. Proc Natl Acad Sci U S A (1992) 2.03
Crystal structure of the DNA polymerase processivity factor of T4 bacteriophage. J Mol Biol (2000) 2.02
Multiple competition reactions for RPA order the assembly of the DNA polymerase delta holoenzyme. EMBO J (1999) 2.00
Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. Am J Physiol Renal Physiol (2000) 1.99
The internal workings of a DNA polymerase clamp-loading machine. EMBO J (1999) 1.98
Devoted to the lagging strand-the subunit of DNA polymerase III holoenzyme contacts SSB to promote processive elongation and sliding clamp assembly. EMBO J (1998) 1.97
An explanation for lagging strand replication: polymerase hopping among DNA sliding clamps. Cell (1994) 1.94
Phase-aberration correction using signals from point reflectors and diffuse scatterers: basic principles. IEEE Trans Ultrason Ferroelectr Freq Control (1988) 1.90
Interaction of the beta sliding clamp with MutS, ligase, and DNA polymerase I. Proc Natl Acad Sci U S A (2001) 1.84
MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene (2003) 1.83
An interaction between DNA ligase I and proliferating cell nuclear antigen: implications for Okazaki fragment synthesis and joining. Proc Natl Acad Sci U S A (1997) 1.82
Replisome assembly at oriC, the replication origin of E. coli, reveals an explanation for initiation sites outside an origin. Mol Cell (1999) 1.82
Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer (2010) 1.79
A molecular switch in a replication machine defined by an internal competition for protein rings. Cell (1996) 1.77
The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br J Urol (1998) 1.76
Processive DNA synthesis by DNA polymerase II mediated by DNA polymerase III accessory proteins. J Biol Chem (1992) 1.72
Fidelity of Escherichia coli DNA polymerase III holoenzyme. The effects of beta, gamma complex processivity proteins and epsilon proofreading exonuclease on nucleotide misincorporation efficiencies. J Biol Chem (1997) 1.70
Replisome assembly reveals the basis for asymmetric function in leading and lagging strand replication. Cell (1996) 1.68
Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med (1996) 1.68
Sliding clamps: a (tail)ored fit. Curr Biol (2000) 1.68
Tip60 is a nuclear hormone receptor coactivator. J Biol Chem (1999) 1.67
Epstein-Barr nuclear antigen 1 mediates a DNA loop within the latent replication origin of Epstein-Barr virus. Proc Natl Acad Sci U S A (1991) 1.66
Written consent about sexual function in men undergoing transurethral prostatectomy. Br J Urol (1994) 1.65
ATP binding to the Escherichia coli clamp loader powers opening of the ring-shaped clamp of DNA polymerase III holoenzyme. J Biol Chem (1998) 1.63
Structural and functional similarities of prokaryotic and eukaryotic DNA polymerase sliding clamps. Nucleic Acids Res (1995) 1.62
Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. Br J Cancer (2011) 1.62
Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Prostate (1998) 1.61
Measuring the elastic modulus of small tissue samples. Ultrason Imaging (1998) 1.58
Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions. Circulation (2001) 1.55
Deletion analysis of the large subunit p140 in human replication factor C reveals regions required for complex formation and replication activities. J Biol Chem (1997) 1.55
Processive replication is contingent on the exonuclease subunit of DNA polymerase III holoenzyme. J Biol Chem (1990) 1.55
Studies on the interactions between human replication factor C and human proliferating cell nuclear antigen. Proc Natl Acad Sci U S A (1999) 1.54
Skin carriage of acinetobacters in Hong Kong. J Clin Microbiol (1999) 1.53
Analysis of the ATPase subassembly which initiates processive DNA synthesis by DNA polymerase III holoenzyme. J Biol Chem (1991) 1.52
Health status of children with moderate to severe cerebral palsy. Dev Med Child Neurol (2001) 1.51
Bladder function in healthy volunteers: ambulatory monitoring and conventional urodynamic studies. Br J Urol (1994) 1.51
Clinical outcome and quality of life following enterocystoplasty for idiopathic detrusor instability and neurogenic bladder dysfunction. Br J Urol (1995) 1.50
Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol (1995) 1.49
Assembly of a chromosomal replication machine: two DNA polymerases, a clamp loader, and sliding clamps in one holoenzyme particle. I. Organization of the clamp loader. J Biol Chem (1995) 1.49
Screening for bacteriuria in urological patients using reagent strips. Br J Urol (1992) 1.48
Battle of the clotbusters. BMJ (1991) 1.47
3-D correlation-based speckle tracking. Ultrason Imaging (2005) 1.46
p53 and p53-regulated genes in bladder cancer. Br J Urol (1998) 1.46
Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol (2007) 1.46
Mucin gene expression in human urothelium and in intestinal segments transposed into the urinary tract. J Urol (2000) 1.45
Constitution of the twin polymerase of DNA polymerase III holoenzyme. J Biol Chem (1991) 1.45
A complex consisting of human replication factor C p40, p37, and p36 subunits is a DNA-dependent ATPase and an intermediate in the assembly of the holoenzyme. J Biol Chem (1997) 1.44
The influence of the proliferating cell nuclear antigen-interacting domain of p21(CIP1) on DNA synthesis catalyzed by the human and Saccharomyces cerevisiae polymerase delta holoenzymes. J Biol Chem (1997) 1.42
Squamous cell carcinoma of skin with a rhabdoid phenotype: a case report. J Clin Pathol (2000) 1.42
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med (2016) 1.41
A model for SOS-lesion-targeted mutations in Escherichia coli. Nature (2001) 1.41
Lipoprotein (a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant (1993) 1.39
Errors in the measurements of T2 using multiple-echo MRI techniques. I. Effects of radiofrequency pulse imperfections. Magn Reson Med (1986) 1.39
Relaxant activity of atriopeptins in isolated guinea pig airway and vascular smooth muscle. Peptides (1985) 1.39
Management issues for debate: the problems in perspective. Aliment Pharmacol Ther (1993) 1.39
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer (1991) 1.39
The effect of prostatectomy on symptom severity and quality of life. Br J Urol (1996) 1.39
DNA polymerase III accessory proteins. V. Theta encoded by holE. J Biol Chem (1993) 1.39
Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. Mol Endocrinol (2000) 1.38
Strain rate imaging using two-dimensional speckle tracking. IEEE Trans Ultrason Ferroelectr Freq Control (2001) 1.37
Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer (2001) 1.37
Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer (2009) 1.36
A nonadrenergic vagal inhibitory pathway to feline airways. Science (1980) 1.35
EBNA1 distorts oriP, the Epstein-Barr virus latent replication origin. J Virol (1992) 1.34
Nuclear LYRIC/AEG-1 interacts with PLZF and relieves PLZF-mediated repression. Oncogene (2009) 1.33
Rectal, bladder and sexual function after mucosal proctectomy with and without a pelvic reservoir for colitis and polyposis. Br J Surg (1982) 1.33
holE, the gene coding for the theta subunit of DNA polymerase III of Escherichia coli: characterization of a holE mutant and comparison with a dnaQ (epsilon-subunit) mutant. J Bacteriol (1994) 1.31
A TOPRIM domain in the crystal structure of the catalytic core of Escherichia coli primase confirms a structural link to DNA topoisomerases. J Mol Biol (2000) 1.30
High frequency optoacoustic arrays using etalon detection. IEEE Trans Ultrason Ferroelectr Freq Control (2000) 1.30
Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer (1987) 1.30
Assembly of a chromosomal replication machine: two DNA polymerases, a clamp loader, and sliding clamps in one holoenzyme particle. II. Intermediate complex between the clamp loader and its clamp. J Biol Chem (1995) 1.30